FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. C014CIP/DIV1/US

SERIAL NO. 09/343,001

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICANT Michael J. Yellin et al.

FILING DATE July 29, 1999 **GROUP** 1644

LIS PATENT DOCUMENTS

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
R	5,961,974	10/5/99	Armitage, et al.	42.4	154.1	May 24, 1994
			_			
		<u> </u>				
		<u> </u>				

EXAMINER

PHULP GAMBEL 9/6/01

DATE CONSIDERED

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY, DOCKET NO. C014CIP/DIV1/US

SERIAL NO. 09/343,001

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICANT Michael J. Yellin et al.

FILING DATE July 29, 1999

GROUP 1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
EXAMINER INITIAL						
N	Press Release from IDEC Pharmaceuticals, Inc. (January 29, 2001)					
M	Kalled, S.L. et al. "Long-term anti-CD154 dosing in nephritic mice is required to maintain survival and inhibit mediators of renal fibrosis", <i>Lupus</i> , 10: 9-22 (2001).					
	<u> </u>					
	<u> </u>					
	<u> </u>					
						
						
						
	<u></u>					
	<u> </u>					

EXAMINER

PHILLIP GAMBEL 9/6/01

DATE CONSIDERED